AKT1

AKT1
National Center for Biotechnology Information, U.S. National Library of Medicine · Public domain · source
Name	AKT1
Altsymbols	PKB, RAC
Uniprot	P31749

AKT1 is a serine/threonine protein kinase that plays a central role in intracellular signaling pathways controlling cell proliferation, survival, metabolism, and growth. First characterized in studies linking growth factor receptors to downstream effectors in signaling cascades, AKT1 is a key effector downstream of phosphoinositide 3-kinase and is implicated in development, oncogenesis, and metabolic regulation. Major research on AKT1 connects to studies in cancer biology, endocrinology, and pharmacology.

Function

AKT1 functions as a critical node in signal transduction linking receptor tyrosine kinases and G protein‑coupled receptors to processes such as cell survival, protein synthesis, and glucose uptake. Studies connecting AKT1 activity to Epidermal growth factor receptor, Insulin receptor, Platelet-derived growth factor receptor, mTOR, and GSK3B illustrate its role in promoting anti-apoptotic signaling and anabolic metabolism. AKT1 phosphorylates substrates including BAD (protein), FOXO1, and TSC2 to modulate apoptosis, transcription, and cell size; its functions intersect with pathways studied in Oncogene research and Cell cycle regulation.

Structure and Isoforms

AKT1 contains an N-terminal pleckstrin homology (PH) domain, a central kinase domain, and a C-terminal regulatory region; structural models and crystallography studies relate to techniques used at institutions like European Molecular Biology Laboratory and Cold Spring Harbor Laboratory. AKT1 belongs to a small family with two paralogs encoded by distinct loci that differ in expression patterns and physiological roles; comparative analyses reference data from Human Genome Project resources and protein databases curated by UniProt. High-resolution structures have been used in drug discovery programs at pharmaceutical companies and academic centers including Pfizer, Novartis, and Massachusetts Institute of Technology.

Regulation and Activation

AKT1 activation is initiated by recruitment to membrane phosphoinositides produced by Phosphoinositide 3-kinase activity downstream of receptors such as Insulin receptor, Vascular endothelial growth factor receptor, and CSF1 receptor. Subsequent phosphorylation by upstream kinases including PDK1 and mTORC2 at conserved residues is required for full catalytic activity; negative regulation involves phosphatases like PTEN and PP2A. Pathways involving PIK3CA mutations, loss-of-function in PTEN, or activation of RAS and SRC family kinases alter AKT1 signaling in contexts examined in translational research at institutions such as National Cancer Institute and Memorial Sloan Kettering Cancer Center.

Clinical Significance

Aberrant AKT1 signaling is implicated in multiple human diseases, most prominently cancer types studied at cancer centers including MD Anderson Cancer Center, Dana–Farber Cancer Institute, and Royal Marsden Hospital. Somatic alterations affecting upstream regulators or AKT1 pathway components contribute to tumorigenesis in breast cancer, colorectal cancer, lung cancer, and glioblastoma. Germline or mosaic activating mutations have been associated with overgrowth disorders documented in clinical genetics literature and treated at centers such as Great Ormond Street Hospital. AKT1 pathway inhibitors have been developed in clinical trials sponsored by companies like AstraZeneca, Roche, and Novartis, and therapeutic strategies often intersect with standard regimens from National Comprehensive Cancer Network guidelines.

Interactions

AKT1 interacts with a network of proteins involved in growth and survival signaling. Reported interactors include PDK1, mTOR, 14-3-3 protein, BAD (protein), FOXO3, MDM2, and scaffold proteins studied in signaling complexes characterized at universities such as Stanford University and University of California, San Francisco. AKT1 engagement with membrane lipids and adaptor proteins ties its function to receptor complexes involving Epidermal growth factor receptor, Insulin receptor substrate 1, and Integrin signaling modules analyzed in cell biology groups at Johns Hopkins University.

Model Organisms and Experimental Studies

Genetic and pharmacological studies in model organisms including Mus musculus, Drosophila melanogaster, and Caenorhabditis elegans have elucidated conserved roles of AKT1-related kinases in growth, lifespan, and metabolism; key findings were published by laboratories at Salk Institute, Max Planck Institute, and Cold Spring Harbor Laboratory. Conditional knockout and transgenic mouse models developed at research centers such as Harvard Medical School and The Scripps Research Institute revealed phenotypes in development, metabolism, and tumorigenesis that informed preclinical studies. Chemical biology approaches and high-throughput screens for AKT1 modulators have been pursued in collaborations involving Broad Institute and pharmaceutical partners.

Category:Human proteins